Beacon Biosignals

Beacon Biosignals provides an end-to-end digital biomarker platform using FDA-cleared at-home EEG devices combined with proprietary machine learning algorithms. Their technology enables remote collection and rapid analysis of brain signals to generate validated endpoints for clinical trials in neurology, psychiatry, and sleep medicine. The company has demonstrated utility across multiple industry collaborations—including novel results presented at major scientific meetings—and supports both retrospective/prospective studies through its large-scale Clinico‑EEG database (>100k patients). Recent milestones include FDA authorization of their Dreem/Waveband device as the first wearable with a predetermined change control plan for continuous algorithm improvement.